Acute oxaliplatin-induced peripheral neuropathy (OIPN), together with the other side effects of chemotherapy, has a negative impact on daily quality of life (QoL) in patients with intestinal or pancreatic cancer.
Why this matters
Peripheral neuropathy is a major side effect of oxaliplatin, a first-line therapy for colorectal and other cancers. OIPN is dose-limiting, and addressing acute OIPN is of utmost importance, as these effects can progress to chronic neuropathy.
The results from this study confirmed that acute OIPN has an influence on daily QoL in patients treated with oxaliplatin and should be used as a basis for quantitative research to assess which symptoms are the most limiting and have the largest influence on QoL.